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Abstract
Background: Reirradiation to the abdomen could potentially play a role in palliation of symptoms
or local control in patients with gastrointestinal malignancies. Our goal was to retrospectively
determine rates of toxicity, freedom from local progression and overall survival in gastrointestinal
cancer patients treated with reirradiation to the abdomen.
Methods: Between November 2002 and September 2008, 13 patients with a prior history of
abdominal radiotherapy (median dose 45 Gy) were treated with reirradiation for recurrent or
metastatic gastrointestinal malignancies. The median interval between the two courses of
radiotherapy was 26 months. Patients were treated with a hyperfractionated accelerated regimen,
using 1.5 Gy fractions twice daily, with a median dose of 30 Gy (range 24-48 Gy). Concurrent
chemotherapy was administered to 8 (62%) patients.
Results: The 1-year rate of freedom from local progression was 50%, and the median duration of
freedom from local progression was 14 months. The 1-year rate of overall survival was 62%, and
the median duration of overall survival was 14 months. One patient developed grade 3 acute
toxicity (abdominal pain and gastrointestinal bleeding), requiring hospitalization during
radiotherapy; subsequently, that patient experienced a grade 4 late toxicity (gastrointestinal
bleeding). No other patients developed grade 3-4 acute or late toxicity or required hospitalization
during radiotherapy.
Conclusion: Hyperfractionated accelerated reirradiation to the abdomen was well-tolerated with
low rates of acute and late toxicity. Reirradiation could play a role in providing a limited duration
of local control in gastrointestinal cancer patients with a history of prior abdominal radiotherapy.
Published: 18 November 2009
Radiation Oncology 2009, 4:55 doi:10.1186/1748-717X-4-55
Received: 6 July 2009
Accepted: 18 November 2009
This article is available from: http://www.ro-journal.com/content/4/1/55
© 2009 Haque et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Radiation Oncology 2009, 4:55 http://www.ro-journal.com/content/4/1/55
Page 2 of 6
(page number not for citation purposes)
Introduction
Multiple studies have demonstrated the safety and efficacy
of reirradiation at various sites of the body, including
head and neck, brain, breast, lung and pelvis [1-15].
Among gastrointestinal malignancies, many studies have
shown the safety and efficacy of pelvic reirradiation for
rectal cancer [11-15]. However, to the best of our knowl-
edge, no studies to date have evaluated the safety and effi-
cacy of reirradiation to the abdomen for gastrointestinal
malignancies. Reirradiation to the abdomen could poten-
tially play a role in palliation of symptoms or local con-
trol. Hence, the goal of this study was to retrospectively
determine rates of toxicity, freedom from local progres-
sion and overall survival in gastrointestinal cancer
patients treated with reirradiation to the abdomen.
Materials and methods
Between November 2002 and September 2008, 13
patients with gastrointestinal cancer and a history of prior
abdominal radiotherapy underwent reirradiation, with a
hyperfractionated accelerated approach, at the University
of Texas M.D. Anderson Cancer Center. The hospital and
radiotherapy records of these patients were reviewed. The
M. D. Anderson Institutional Review Board approved this
study.
Patient Characteristics
Patient characteristics are shown in Table 1. The median
age at the time of retreatment was 56 years (range 37-80
years). The diagnosis was pancreatic adenocarcinoma in 3
patients, colon adenocarcinoma colon in 3 patients,
Table 1: Patient and Treatment Characteristics
Characteristic Median (Range) or Number of Patients (%)
Age at Retreatment (years) 56 (37-80)
Gender
Male 9 (69%)
Female 4 (31%)
Pathology
Pancreatic adenocarcinoma 3 (23%)
Colon carcinoma 3 (23%)
Cholangiocarcinoma 2 (15%)
Others* 5 (38%)
Prior Radiotherapy Dose
30 Gy (10-12 fractions) 2 (15%)
35 Gy (14 fractions) 2 (15%)
45 Gy (25 fractions) 4 (31%)
50.4 Gy (28 fractions) 5 (38%)
Retreatment Interval (months) 26 (5-83)
Retreatment Dose**
24 Gy 1 (8%)
30 Gy 6 (46%)
34.5 Gy 1 (8%)
39 Gy 4 (31%)
48 Gy 1 (8%)
Concurrent Chemotherapy
Yes 8 (62%)
No 5 (38%)
Indication for Retreatment
Palliation of Pain 5 (38%)
Palliation of Bleeding 4 (31%)
Definitive (Not candidate for other treatments) 3 (23%)
Consolidation after Chemotherapy 1 (8%)
* Ampullary, gastric, duodenal, small bowel, and pancreatic neuroendocrine
** Retreatment was given in 1.5 Gy twice daily fractionsRadiation Oncology 2009, 4:55 http://www.ro-journal.com/content/4/1/55
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cholangiocarcinoma in 2 patients, and ampullary adeno-
carcinoma, gastric adenocarcinoma, duodenal adenocar-
cinoma, small bowel adenocarcinoma, and pancreatic
neuroendocrine carcinoma, in 1 patient each.
Prior radiotherapy records were obtained and reviewed in
all cases at the time of retreatment. The median dose of
prior radiotherapy was 45 Gy (range 30-50.4 Gy). The
prior radiotherapy dose was 30 Gy in 2.5-3 Gy fractions in
2 patients, 35 Gy in 2.5 Gy fractions in 2 patients, 45 Gy
in 1.8 Gy fractions in 4 patients and 50.4 Gy in 1.8 Gy
fractions in 5 patients. Prior radiation was given with a
definitive intent in 9 patients and for palliation in 4
patients. The median interval between the two courses of
radiotherapy was 26 months (range 5-83 months).
At the time of reirradiation, 8 (62%) patients had recur-
rent disease and 5 (38%) patients had metastatic disease.
Prior to reirradiation, patients had received a median of 2
(range 0-4) different regimens of chemotherapy, not
including concurrent chemotherapy given with radiation.
Reirradiation was administered for palliation of pain in 5
patients, palliation of bleeding in 4 patients, definitive
treatment in 3 patients who were not candidates for other
therapies, and consolidative treatment after chemother-
apy in 1 patient.
Treatment
All patients underwent computed tomography (CT) sim-
ulation. Patient-specific information about reirradiation
is shown in Table 2. Patients were treated with 150 cGy
fractions twice daily, with an interval ≥ 6 hrs between frac-
tions. The prescribed dose of reirradiation was 30 Gy in 7
patients, 39 Gy in 5 patients and 48 Gy in 1 patient. The
fractionation regimen of 150 cGy twice daily and doses of
30-39 Gy were selected based on a similar regimen used
for pelvic reirradiation at our institution [16]. The specific
dose of 30 or 39 Gy was chosen by the attending radiation
oncologist, based on the interval from the previous course
of radiation and dose to critical structures. A higher dose
of 48 Gy was selected in one patient because of limited
overlap with prior fields and limited dose to critical struc-
tures. Radiation therapy was stopped early in 2 patients
because of acute toxicity. Hence, the administered reirra-
diation dose was 24 Gy in 1 patient, 30 Gy in 6 patients,
34.5 Gy in 1 patient, 39 Gy in 4 patients and 48 Gy in 1
patient. The median administered dose of reirradiation
was 30 Gy. In all cases, patients were reirradiated for recur-
rence or metastasis from the same primary tumor for
which they were initially treated. The site of retreatment
was para-aortic/paracaval nodes in 4 patients, pancreas in
3 patients, stomach in 2 patients, and the superior
mesenteric region, duodenum, liver metastasis and
abdominal wall mass, in 1 patient each. Among the 13
patients, the reirradiated region was completely within
the previously treated volume in 9 patients, and the reir-
radiated region partially overlapped with the previously
treated volume in 4 patients. Radiation therapy was deliv-
ered using intensity-modulated radiation therapy (IMRT)
in 5 patients, 4-field conformal technique in 4 patients,
wedge-pair in 2 patients, 5-field conformal technique in 1
patient, and two oblique fields in 1 patient. Reirradiation
was administered to the gross tumor volume (GTV) with
a 2-3 cm block margin for conformal plans. A margin of
1.5-2 cm was added to the GTV to form the planning tar-
get volume (PTV) for IMRT plans. Radiation therapy was
delivered using 6-18 MV photons. In selected cases (N =
7), cumulative dose-volume histograms were obtained for
the two courses of radiation therapy, with particular atten-
tion given to the cumulative doses to the spinal cord, kid-
neys, liver and bowel. Typical cumulative dose constraints
included maximum dose to the spinal cord = 46 Gy, V20
for at least one kidney <33% and V30 for liver < 50%,
although these could be exceeded at the discretion of the
attending radiation oncologist, especially if there was a
prolonged interval between the two courses of radiation
therapy. Concurrent chemotherapy was administered to 8
(62%) patients, of whom 7 received capecitabine, and 1
received gemcitabine and erlotinib. None of the patients
underwent surgical resection of the irradiated area.
Follow-up
Follow-up information was obtained from hospital
records and radiation therapy department records. Fol-
low-up information was also obtained from the M. D.
Anderson Tumor Registry, which collects information on
patients annually through letters, phone calls, and Bureau
of Vital Statistics records. The median follow-up interval
was 8 (range 3-26) months.
Statistical Analysis
Acute and late toxicity was graded using the Common Ter-
minology Criteria for Adverse Events version 3.0 [17].
Local progression was defined as any radiographic pro-
gression within the treated field. The rates of freedom
from local progression and overall survival were estimated
by Kaplan-Meier methods [18]. All time intervals were cal-
culated from the date of completion of reirradiation.
Results
Local Control and Survival
Seven (54%) of the 13 patients developed local progres-
sion. The 1-year actuarial rate of freedom from local pro-
gression was 50% (Figure 1). The median duration of
freedom from local progression was 14 months. There
were 10 deaths (77%) among the 13 patients. The 1-year
actuarial overall survival rate was 62% (Figure 2). The
median duration of overall survival was 14 months.Radiation Oncology 2009, 4:55 http://www.ro-journal.com/content/4/1/55
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Toxicity
Only 1 patient (8%) developed grade 3 acute toxicity
(abdominal pain and bleeding from gastrojejunal anasto-
mosis) during chemoradiation; this patient required hos-
pitalization for 4 days and termination of radiation
therapy before completion of the prescribed course. No
other patient developed grade 3-4 acute toxicity or was
hospitalized for acute toxicity. Only one patient devel-
oped grade 2 acute toxicity (duodenal ulceration and stric-
ture); radiation therapy was stopped early in this patient
Table 2: Patient-specific Retreatment Characteristics
Patient No. Retreatment 
Site
Tumor Size 
(cm)*
Retreatment 
Dose (Gy)
Retreatment 
Interval 
(months)
Retreatment DVH Cumulative DVH
1 Duodenum 7 × 7 × 5 30 42 Kidneys V20 0%, 38%, 
Liver V30 0%, Max. cord 
dose 15 Gy
2 Stomach 10 × 4 × 2 30 29 Kidneys V20 0%, 0%, Liver 
V30 5%, Max. cord dose 
20 Gy
3 Liver 5 × 5 × 6 48 45 Kidneys V20 0%, 0%, Liver 
V30 25%, Max. cord dose 
3 Gy
Kidneys V20 0%, 0%, Liver 
V30 58%, Max. cord dose 
42 Gy
4 Stomach 10 × 9 × 10 30 5 Kidneys V20 0%, 2%, Max. 
cord dose 12 Gy
5S u p e r i o r  
mesenteric
5 × 3 × 3 39 25 Kidneys V20 0%, 0%, Liver 
V30 0%, Max. cord dose 
32 Gy
6 Abdominal wall 7 × 3 × 10 30 26 Max. cord dose 12 Gy
7 Para-aortic/caval 4 × 3 × 3 39 28 Kidneys V20 7%, 21%, 
Max. cord dose 23 Gy
Kidneys V20 22%, 32%, 
Max. cord dose 39 Gy
8 Pancreas 8 × 6 × 5 34.5 22 Kidneys V20 7%, 17%, 
Liver V30 5%, Max. cord 
dose 27 Gy
Kidneys V20 9%, 23%, 
Liver V30 22%, Max. cord 
dose 43 Gy
9 Pancreas 6 × 6 × 6 39 83 Kidney V20 0%, Liver V30 
0%, Max. cord dose 12 
Gy
Kidney V20 0%, Liver V30 
12%, Max. cord dose 39 
Gy
10 Para-aortic/caval 9 × 10 × 17 30 36 Max. cord dose 7 Gy
11 Para-aortic/caval 9 × 6 × 8 30 26 Kidneys V20 0%, 0%, Liver 
V30 20%, Max. cord dose 
18 Gy
Kidneys V20 14%, Liver 
V30 72%, Max. cord dose 
46 Gy
12 Pancreas 6 × 4 × 6 24 12 Kidneys V20 0%, 0%, Liver 
V30 0%, Max. cord dose 
17 Gy
Kidneys V20 8%, 24%, 
Liver V30 33%, Max. cord 
dose 46 Gy
13 Para-aortic/caval 5 × 6 × 5 39 11 Kidneys V20 5%, 8%, Liver 
V30 4%, Max. cord dose 
23 Gy
Kidneys V20 18%, 20%, 
Liver V30 42%, Max. cord 
dose 38 Gy
DVH: Dose volume histogram
Max.: Maximum
* Maximum lateral × anterioposterior × craniocaudal dimensions, respectivelyRadiation Oncology 2009, 4:55 http://www.ro-journal.com/content/4/1/55
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to prevent progression of the ulcer. The remaining 11
patients completed their prescribed course of radiation
therapy.
The patient with grade 3 acute toxicity subsequently devel-
oped grade 4 late toxicity (bleeding from the gastrojejunal
anastomosis), two months after completion of reirradia-
tion. The gastrojejunal anastomosis had received a cumu-
lative maximum dose of 63 Gy in this patient. The patient
was initially treated with endoscopic clips, epinephrine
and coagulation, and then required a surgical revision of
gastrojejunostomy. This patient had no subsequent epi-
sodes of gastrointestinal bleeding. No other patient devel-
oped grade 3-4 late toxicity.
Discussion
We have hereby reported the first study on reirradiation to
the abdomen for gastrointestinal cancers. Patients treated
with reirradiation had a limited overall survival, with a
median survival of 14 months, which reflects the poor
prognosis of patients with recurrent or metastatic abdom-
inal malignancies. Reirradiation provided local control
for a limited duration, with a median duration of freedom
from local progression of 14 months. However, this dura-
tion of local control was clinically significant, taking into
consideration the limited life expectancy in these patients.
Reirradiation provided these patients durable local con-
trol that lasted for the majority of their remaining life
without significant increase in morbidity.
Reirradiation was well-tolerated with only one patient
experiencing grade 3-4 acute and late toxicity. In addition,
one patient developed grade 2 acute toxicity. These toxic-
ity events involved gastrointestinal bleeding or ulceration.
Patients treated with reirradiation may have a higher risk
of developing gastrointestinal bleeding and ulceration,
compared to patients not exposed to prior radiation ther-
apy. Hence, we need to be cognizant about the risk of
bleeding and ulceration in patients treated with abdomi-
nal reirradiation, especially around the duodenum or jeju-
nal anastomosis.
We used a hyperfractionated accelerated regimen to
deliver radiation therapy, with 150 cGy fractions, given
twice daily. We recently reported outcomes in 50 rectal
cancer patients treated with pelvic reirradiation with an
identical regimen, with a total dose of 30-39 Gy [16]. Pel-
vic reirradiation was well-tolerated, with grade 3 acute
toxicity occurring in 4% and grade 3-4 late toxicity occur-
ring in 26% of patients. The median duration of freedom
from local progression was 21 months and the median
overall survival was 26 months. Rectal cancer patients
likely had superior outcomes because of more favorable
tumor biology compared to abdominal cancers, and
because many of the rectal cancer patients underwent sur-
gical resection in addition to radiation therapy. Neverthe-
less, we have now demonstrated in two separate sites of
the body that reirradiation can be safely administered
using a hyperfractionated accelerated approach, with 150
cGy twice daily fractions.
This study had several limitations. The number of patients
was small, and there was considerable heterogeneity in
tumor type and site of reirradiation. Hence, it is difficult
to draw firm conclusions regarding the local control and
Kaplan-Meier estimates of overall survival in patients treated  with abdominal reirradiation Figure 2
Kaplan-Meier estimates of overall survival in patients 
treated with abdominal reirradiation.
Kaplan-Meier estimates of freedom from local progression in  patients treated with abdominal reirradiation Figure 1
Kaplan-Meier estimates of freedom from local pro-
gression in patients treated with abdominal reirradi-
ation.Radiation Oncology 2009, 4:55 http://www.ro-journal.com/content/4/1/55
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survival outcomes in this study. Moreover, since patients
received systemic therapy in addition to radiation therapy,
it is difficult to surmise how much radiation contributed
to the overall outcomes. Toxicity rates were assessed based
on a review of hospital and departmental records, and
therefore, may have been underestimated. The median
follow-up interval was relatively short, and any patients
who achieve long-term survival after reirradiation could
potentially have higher rates of late toxicity. In spite of
these limitations, this study shows that abdominal reirra-
diation could be a potential treatment option in selected
patients with gastrointestinal malignancies. Of note, only
13 patients were treated with this approach in a period of
about 6 years at a large institution. Careful patient selec-
tion clearly plays an important role in determining who
might benefit from this treatment.
In conclusion, our study showed that abdominal reirradi-
ation was well-tolerated with low rates of acute and late
toxicity. Abdominal reirradiation appeared to provide
local control, albeit with a limited duration. We suggest
that abdominal reirradiation could have many potential
applications in selected patients with recurrent or meta-
static gastrointestinal cancers. Reirradiation may help in
palliation of symptoms, such as pain or bleeding. In
patients with isolated areas of disease that are refractory to
chemotherapy, reirradiation could help achieve local con-
trol. In patients that have a good response to chemother-
apy, reirradiation could have a consolidative role. Further
studies are warranted to evaluate the role of abdominal
reirradiation in these settings. Further studies are also
needed to confirm the safety of abdominal reirradiation.
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